Latest Breaking News On - Lynn kramer - Page 9 : comparemela.com

Antibody is first of three tau drugs to be evaluated Clinical trial participant Taylor Hutton (left) meets with Randall J. Bateman, MD, director of the global DIAN-TU Alzheimer’s clinical trial in 2018. Hutton’s family has a history of early-onset Alzheimer’s disease. The DIAN-TU is launching three new arms to evaluate experimental Alzheimer’s drugs targeting the protein tau. (Photo: Matt Miller/School of Medicine) March 15, 2021 SHARE A worldwide clinical trial aimed at finding treatments for Alzheimer’s disease has expanded to include investigational drugs targeting a harmful form of the brain protein tau. The trial, known as the Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU) and led by Washington University School of Medicine in St. Louis, launched in 2012 as the first prevention trial for Alzheimer’s disease. Originally focused on amyloid-based therapies, it was funded by the National Institute on Aging (NIA) of the National Institutes of Heal

Randallj batemanMariac carrilloRichardj hodesLynn kramerFred millerNational institutes of healthAlzheimer network trials unitAlzheimer associationEisai coWashington university school of medicineNational institute on agingEisai neurology business groupWashington university schoolNational instituteNational institutesJoanne knight distinguished professor